BiotechTube
Home/Pipeline/Erleada (apalutamide)

Erleada (apalutamide)

Prostate Cancer

ApprovedCommercial

Key Facts

Indication
Prostate Cancer
Phase
Approved
Status
Commercial
Company
Johnson & Johnson

About Johnson & Johnson

Founded in 1886, Johnson & Johnson operates as a multinational healthcare corporation headquartered in New Brunswick, New Jersey. The company's pharmaceutical division, Janssen, is a global leader in oncology, immunology, and neuroscience with blockbuster drugs like Stelara, Darzalex, and Remicade. J&J combines deep scientific expertise with extensive global reach, serving patients in over 175 countries while maintaining one of the industry's strongest R&D pipelines.

View full company profile

Therapeutic Areas

OncologyImmunologyNeuroscienceInfectious DiseasesCardiovascularMetabolism

Other Prostate Cancer Drugs

DrugCompanyPhase
Nubeqa (darolutamide)BayerApproved
Xtandi (enzalutamide)Astellas PharmaApproved
Proxalutamide (HS-10370)Hansoh PharmaPhase 3
Darolutamide (Nubeqa)Orion CorporationApproved
Relacorilant + EnzalutamideCorcept TherapeuticsPhase 2
NBTXR3NanobiotixPhase 1/2
Praluzatamab ravtansine (CX-2009)CytomX TherapeuticsPhase 1/2
Bavdegalutamide (ARV-110)ArvinasPhase 2
ARV-766ArvinasPhase 2
Alpha DaRTAlpha Tau MedicalPhase 1/2
Prognostic Genomic TestsEurobio ScientificCommercial
SelinexorKaryopharm TherapeuticsClinical Trials